%PDF-1.5
%
167 0 obj
<>
endobj
166 0 obj
<>stream
application/pdf
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study†
2016-06-21T12:45:09+05:30
Arbortext Advanced Print Publisher 10.0.1465/W Unicode
2017-01-11T04:00:12-08:00
2017-01-11T04:00:12-08:00
Acrobat Distiller 10.1.16 (Windows)
uuid:064c0037-f48a-413c-b10f-4f7c3a3a5b71
uuid:4f7d1ae4-1dd2-11b2-0a00-b0007801a2ff
endstream
endobj
168 0 obj
<>
endobj
160 0 obj
<>
endobj
2 0 obj
<>
endobj
162 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
43 0 obj
<>/Font<>/ProcSet[/PDF/Text]/Properties<>>>/Rotate 0/Type/Page>>
endobj
63 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
68 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
86 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
95 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
104 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
242 0 obj
<>stream
HWMs6W(n
5HL;=U-ZFZK/BrvMWnzh6_M;HT*4'&Yԥ~DdmO%,}jzW7_it<1Fo.%yX,?XG+X^T
n*[,}7?|K6v/{i]DLfe:$YU1|i1qߵ;V:D$!2tr+Qh>ɦ
_u[^" C0^;3,7>6At%aHܝ~w*kOu?p}<68uAP6}߸>PRk #m՟84*a+@C:*SO}dJIe~l/jEd:s-hHb
щoI(ZwPafܬ߷0(4G,v t¹"p PI\v#>Jkd-LIfh"1%V1U>D^ML!Mݷ}$෧CCHs|rF/OOá.,1NJ*u6zq*+{ENFC!i3-H0bjτ7QJqV4Ki0K빫T{MN7U''&]Ei^o&LFq"`Z
z&::lp1y;gryqq6ri]$"}u-sL(Z
De@-ep#`Sr(RP!NdIwYLe 1sr
~ &06ؗ0^-]^ }iΞBhx'6sQc ][r,חtgHDe!!L}<W0'/ #\T^ =v,b}y)~N=ΣL\)u27<5AѣoЮԬ0 V-Cn}ӱkdDJRP%?/N,Z!O<